T CELL RECEPTOR AFFINITY VIA FREE ENERGY MINIMIZATION

描述：（改编自申请人的摘要）病毒性疾病，对于一个 许多原因，逃避了广泛有效的抗生素治疗 可用于细菌，并且相对较少可以通过接种疫苗来预防。 本项目的长期目标是设计和生产可溶性、高 亲和性T细胞受体（TcR）或TcR样蛋白（例如，抗体） 靶向临床重要的主要组织相容性复合物（MHC）-肽 结构这样的TcR或TcR样分子可以直接用于体外免疫。 诊断病毒感染，并可与毒素结合杀死病毒 感染的细胞。该项目第一阶段的目标是应用 结合自由能最小化的计算方法 设计用于MHC-肽复合物的高亲和力TcR。计算 在第一阶段实施和验证的算法和软件将用于 设计新的TcR序列，将在项目的第二阶段生产。 拟议商业应用：不可用

DESCRIPTION: (Adapted from the applicant's abstract) Viral diseases have, for a number of reasons, eluded the sorts of broadly effective antibiotic treatments available for bacteria, and relatively few can be prevented by vaccinations. The long-term goal of this project is to design and produce soluble, high affinity T cell receptors (TcR) or TcR-like proteins (e.g., antibodies) targeting clinically important Major Histocompatibility Complexes (MHC)-peptide structure. Such TcR or TcR-like molecules can be used directly for in vitro diagnostics of viral infection, and can be combined with toxins to kill virally infected cells specifically. The goal of Phase I of this project is to apply recently developed computational methods for binding free energy minimization to the design of high affinity TcR for MHC-peptide complexes. The computational algorithms and software implemented and validated in Phase I will be used to design novel TcR sequences, which will be produced in Phase II of the project. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE